miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer.
about
Hallmarks of cancer and AU-rich elementsAdaptive and maladaptive expression of the mRNA regulatory protein HuRCurrent Evidence and Future Perspectives on HuR and Breast Cancer Development, Prognosis, and TreatmentMultiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosisA balancing act: RNA binding protein HuR/TTP axis in endometriosis patients.Regulation of the mRNA half-life in breast cancerTristetraprolin represses estrogen receptor α transactivation in breast cancer cellsKrüppel -like factor 8 is a stress-responsive transcription factor that regulates expression of HuR.Post-transcriptional up-regulation of PDGF-C by HuR in advanced and stressed breast cancer.Tristetraprolin inhibits the growth of human glioma cells through downregulation of urokinase plasminogen activator/urokinase plasminogen activator receptor mRNAsA post-transcriptional mechanism pacing expression of neural genes with precursor cell differentiation status.High-throughput sequencing of pituitary and hypothalamic microRNA transcriptome associated with high rate of egg productionCan we observe changes in mRNA "state"? Overview of methods to study mRNA interactions with regulatory proteins relevant in cancer related processes.Tristetraprolin suppresses the EMT through the down-regulation of Twist1 and Snail1 in cancer cellsTristetraprolin expression and microRNA-mediated regulation during simian immunodeficiency virus infection of the central nervous systemRNA binding protein, tristetraprolin in a murine model of recurrent pregnancy loss.Regulation of cellular processes by interleukin-16 in homeostasis and cancer.Post-transcriptional control of cytokine gene expression in health and disease.Dysregulation of TTP and HuR plays an important role in cancers.Post-transcriptional regulation of cytokine and growth factor signaling in cancer.Posttranscriptional control of the chemokine receptor CXCR4 expression in cancer cells.Predictive and prognostic significance of cytoplasmic expression of ELAV-like protein HuR in invasive breast cancer treated with neoadjuvant chemotherapy.UTRly malignant: mRNA stability and the invasive phenotype in breast cancer.Modulation of the prostaglandin-endoperoxide synthase 2 gene expression by variant haplotypes: influence of the 3'-untranslated region.MiR-29a: a potential therapeutic target and promising biomarker in tumors.Posttranscriptional control of airway inflammation.Emerging role of HuR in inflammatory response in kidney diseases.Post-transcriptional regulation of ERBB2 by miR26a/b and HuR confers resistance to tamoxifen in estrogen receptor-positive breast cancer cells.Dysregulation of tristetraprolin and human antigen R promotes gastric cancer progressions partly by upregulation of the high-mobility group box 1.
P2860
Q26744134-2EA32B65-9C5F-4230-8F91-47508016DF47Q26865703-4D04D3F2-367F-4BFD-9DE1-A75FC4FBABDCQ28075325-FAFF812A-BAB4-4EE1-A4E5-1CDD64C93512Q28290458-2B7D046C-5182-45BD-8A23-604AC03F2245Q33919012-82F2FBF8-321E-43C5-8768-17AEB83196FEQ34023658-A586E193-546B-4E69-B4C4-9CA8E255120EQ34075981-B25E654B-65AD-4C71-B8CA-6D8A6A772833Q34117694-7B3F7CAB-E646-4232-B7D2-47E867406BA9Q34685349-79A5224E-2091-46F6-B830-451B952E854BQ35093788-A0A9C5C2-BA22-4F1E-8E90-5F4EFF5C731FQ35863576-5CB0515A-CE32-4587-B261-992F83E481E1Q36320924-30D12106-EE32-4DD8-BB16-35ACF0A538F1Q36431066-90B2F95D-F061-4171-839B-088290B1A509Q36962457-7D452052-652E-4DE2-8A8A-99CC06959C51Q37153550-C56FCCC2-FFF0-4031-B4C4-4754BBBFC6ACQ37687246-2AD6598E-3EE5-4027-A1BC-4BACE181F478Q38124813-F22EAD82-251F-43E5-9D73-D60CDD28E0F7Q38623564-524D0DE9-F951-4258-8FED-1E63A804386FQ38958552-1243A13E-7C42-41A5-B82B-56AC175C24C0Q39036700-15E8C1C9-67C2-4EF7-9157-8D092E7613BFQ42845461-BB33B479-FDBC-4DB5-9B0D-27D8234140CEQ45929654-FDDBD591-B9B4-4659-8B67-584F683B0E15Q45970574-A22D9AFA-9554-4611-B986-F08BAABABC4EQ47099229-89DC5423-03A9-4FB4-B9B6-A019545A99F4Q47568135-26E73EA8-580D-4A3D-B1B1-7D14A4FE898CQ47601835-0BB90156-1E3A-4F0F-84E8-333B119BC405Q47801949-9B3A7728-CA2C-45AC-9E8C-5BEAD3474F38Q47997363-1E45C342-DE86-43E4-8DB5-483DCDA807E5Q55408888-DEA227DC-4D61-4FE3-9EBD-13E195A8229E
P2860
miR-29a inhibition normalizes HuR over-expression and aberrant AU-rich mRNA stability in invasive cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 21 March 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
miR-29a inhibition normalizes ...... stability in invasive cancer.
@en
miR-29a inhibition normalizes ...... stability in invasive cancer.
@nl
type
label
miR-29a inhibition normalizes ...... stability in invasive cancer.
@en
miR-29a inhibition normalizes ...... stability in invasive cancer.
@nl
prefLabel
miR-29a inhibition normalizes ...... stability in invasive cancer.
@en
miR-29a inhibition normalizes ...... stability in invasive cancer.
@nl
P2093
P2860
P356
P1476
miR-29a inhibition normalizes ...... stability in invasive cancer.
@en
P2093
Khalid S A Khabar
Maha Al-Ghamdi
Norah Al-Souhibani
Wijdan Al-Ahmadi
P2860
P356
10.1002/PATH.4178
P577
2013-03-21T00:00:00Z